Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising therapeutic strategy for the treatment of brain disorders. However, the development of potent small ligands for the TrkB receptor has proven to be difficult. By using a peptidomimetic approach, we developed a highly potent and selective TrkB inhibitor, cyclotraxin-B, capable of altering TrkB-dependent molecular and physiological processes such as synaptic plasticity, neuronal differentiation and BDNF-induced neurotoxicity. Cyclotraxin-B allosterically alters the conformation of TrkB, which leads to the inhibition of both BDNF-dependent and -independent (basal) activities. Finally, systemic administration of cyclotraxin-B to mice results in TrkB inhibition in the brain with specific anxiolytic-like behavioral effects and no antidepressant-like activity. This study demonstrates that cyclotraxin-B might not only be a powerful tool to investigate the role of BDNF and TrkB in physiology and pathology, but also represents a lead compound for the development of new therapeutic strategies to treat brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Cyclotraxin-B inhibits normal and deleterious cellular signaling events associated with TrkB but not TrkA nor TrkC. (A-D) Cyclotraxin-B inhibits TrkB- but not TrkA- nor TrkC-dependent neurite outgrowth. (A) Representative photomicrographs of nnr5 PC12-TrkB cells treated for 48 h with cyclotraxin-B and/or BDNF. 20× magnification. (B) Quantitative analysis of BDNF-induced neurite outgrowth in presence of increasing concentrations of cyclotraxin-B. Data are mean ± s.e.m. (sixplicates; n = 5). (C) Quantitative analysis and representative western blot of total and phospho-MAPK in nnr5 PC12-TrkB cells treated as indicated. Data are mean ± s.e.m. (n = 4) and are expressed in percentage of basal condition; *** P<0.001 compared to control; §§§ P<0.001, compared to BDNF. (D) nnr5 PC12-TrkA and -TrkC cells were incubated with cyclotraxin-B (1 µM) in presence or not of NGF or NT-3, respectively. (E) Cyclotraxin-B prevents BDNF-induced neurons death. Cortical neurons were treated with cyclotraxin-B or BDNF, as described in methods. Data are mean ± s.e.m. (sixplicates, n = 5) expressed in percentage of control. *** P<0.001 compared to control; §§§ P<0.001, compared to BDNF. (F) Cyclotraxin-B inhibits cap-dependent protein translation in cortical neurons. [35S]-methionine incorporation into proteins (white bars) was measured in cortical neurons exposed to cyclotraxin-B, K252a and BDNF, as indicated. Phosphorylation of eIF4E was quantified by immunoblots (black bars). Data are mean ± s.e.m. (triplicates, n = 5) and are expressed in percentage of basal condition; * P<0.05, ** P<0.01, *** P<0.001, compared to respective basal condition; § P<0.05, §§ P<0.01, compared to respective BDNF condition. Inset shows correlations between TrkB-dependent protein synthesis and eIF4E phosphorylation. (1) K252a, (2) cyclotraxin-B, (3) basal, (4) BDNF + cyclotraxin-B, (5) BDNF.](https://figures.cochat.ai/paper-figures/3670adbaa54842babfec64f260d9d557/cyclotraxin-b-the-first-highly-potent-and-selective-trkb-inhibitor-has-figure-5.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While one study has observed anxiolytic properties, this molecule did not seem to display clear antidepressant effects (Cazorla et al. 2010)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Cazorla et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,063
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307 · cited 2×
“Our observations are in line with two recent studies demonstrating that mice susceptible to stress-related disorders after chronic social defeat have an overactivity of BDNF/TrkB signaling in their reward system [40,41].”
BackgroundResultEssential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 2×
“Our observations are in line with two recent studies demonstrating that mice susceptible to stress-related disorders after chronic social defeat have an overactivity of BDNF/TrkB signaling in their reward system [40,41].”
BackgroundResultHippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., & Bonhoeffer, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8856 · Cited by 1,426 · cited 1×
“have reported a reduction within the same range, from about 190% to 135%, using BDNF knockout mice [51].”
MethodGenetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior
Chen, Z.-Y., Jing, D., Bath, K. G., Ieraci, A., Khan, T., Siao, C.-J., Herrera, D. G., Toth, M., Yang, C., McEwen, B. S., et al. (2006) · Science · doi:10.1126/science.1129663 · Cited by 1,340
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 4×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
BackgroundInfluentialBDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis
Bramham, C. R., & Messaoudi, E. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.003 · Cited by 1,193 · cited 2×
“modulation of synaptic plasticity [8].”
Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958 · cited 1×
“Competition binding studies were done mainly as previously described [55].”
MethodMurer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874 · cited 1×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
Backgroundp75 and Trk: A two-receptor system
Chao, M. V., & Hempstead, B. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93922-k · Cited by 857
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800 · cited 1×
“Our results are also consistent with previous studies using transgenic mice lacking TrkB receptors for which no alteration in depressive-like behaviors could be observed [46,47].”
ResultEssential Role for TrkB Receptors in Hippocampus-Mediated Learning
Minichiello, L., Korte, M., Wolfer, D., Kühn, R., Unsicker, K., Cestari, V., Rossi-Arnaud, C., Lipp, H.-P., Bonhoeffer, T., & Klein, R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80853-3 · Cited by 799
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB
Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004) · Nature · doi:10.1038/nature02765 · Cited by 607 · cited 1×
“In addition, basal more than BDNF-dependent TrkB activity may play a critical role in the etiology of some pathologies such as epileptogenesis [9], amyotrophic lateral sclerosis [10] and cancer metastases [50].”
BackgroundRole of brain-derived neurotrophic factor in Huntington's disease
ZUCCATO, C., & CATTANEO, E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.003 · Cited by 552 · cited 3×
“Given its trophic effects on neurons and its central role in highorder cognitive functions, BDNF has rapidly emerged as a key element in the pathophysiology of numerous brain disorders, including neurological disorders [e.g. epileptogenesis [9]], neurodegenerative diseases [e.g. amyotrophic lateral sclerosis [10], Hun…”
BackgroundActivation of Trk neurotrophin receptors in the absence of neurotrophins
Lee, F. S., & Chao, M. V. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061020198 · Cited by 482 · cited 4×
“glucocorticoids or the inorganic ion Zinc [2,3,4,5,6,7].”
BackgroundInfluentialNeurotrophins and Time: Different Roles for TrkB Signaling in Hippocampal Long-Term Potentiation
Kang, H., Welcher, A. A., Shelton, D., & Schuman, E. M. (1997) · Neuron · doi:10.1016/s0896-6273(00)80378-5 · Cited by 481 · cited 1×
“antiserum [38], cyclotraxin-B did not alter either synaptic strength or presynaptic functions (Fig.”
BackgroundExpression and function of TRK-B and BDNF in human neuroblastomas.
Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.759 · Cited by 423 · cited 1×
“ECFP) by cloning the full human TrkB sequence [52] (kindly”
BackgroundGraham, D. L., Edwards, S., Bachtell, R. K., DiLeone, R. J., Rios, M., & Self, D. W. (2007) · Nature Neuroscience · doi:10.1038/nn1929 · Cited by 401
Potentiated Necrosis of Cultured Cortical Neurons by Neurotrophins
Koh, J.-Y., Gwag, B. J., Lobner, D., & Choi, D. W. (1995) · Science · doi:10.1126/science.7725105 · Cited by 365 · cited 1×
“shown that excess BDNF can induce neuronal death through activation of TrkB but not p75 [34,37].”
BackgroundTAT transduction: the molecular mechanism and therapeutic prospects
Gump, J. M., & Dowdy, S. F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.002 · Cited by 356 · cited 1×
“In order to allow its delivery to the brain after intravenous injections, we fused the non-toxic transduction domain of the tat protein from the HIV type 1 [39] to cyclotraxin-B (tat-cyclotraxin-B).”
MethodNeurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335 · cited 1×
“amyotrophic lateral sclerosis [10], Huntington [11], Alzheimer’s and Parkinson’s diseases [12]] and psychiatric disorders [e.”
BackgroundZakharenko, S. S., Patterson, S. L., Dragatsis, I., Zeitlin, S. O., Siegelbaum, S. A., Kandel, E. R., & Morozov, A. (2003) · Neuron · doi:10.1016/s0896-6273(03)00543-9 · Cited by 334
Structure of Nerve Growth Factor Complexed with the Shared Neurotrophin Receptor p75
He, X.-L., & Garcia, K. C. (2004) · Science · doi:10.1126/science.1095190 · Cited by 323 · cited 1×
“and Trk receptors may induce receptors aggregation in lipid rafts, convergence of signaling pathways or recruitments of different intracellular adaptors”
BackgroundHempstead, B. L., Rabin, S. J., Kaplan, L., Reid, S., Parada, L. F., & Kaplant, D. R. (1992) · Neuron · doi:10.1016/0896-6273(92)90241-5 · Cited by 318 · cited 1×
“but also from increases in receptor density that lead to spontaneous autophosphorylation”
BackgroundWehrman, T., He, X., Raab, B., Dukipatti, A., Blau, H., & Garcia, K. C. (2007) · Neuron · doi:10.1016/j.neuron.2006.09.034 · Cited by 314 · cited 1×
“It has been proposed that coexpression of p75 and Trk receptors may induce receptors aggregation in lipid rafts, convergence of signaling pathways or recruitments of different intracellular adaptors [48,49].”
BackgroundConditional Deletion of TrkB but Not BDNF Prevents Epileptogenesis in the Kindling Model
He, X.-P., Kotloski, R., Nef, S., Luikart, B. W., Parada, L. F., & McNamara, J. O. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.019 · Cited by 303 · cited 3×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
BackgroundBerghuis, P., Dobszay, M. B., Wang, X., Spano, S., Ledda, F., Sousa, K. M., Schulte, G., Ernfors, P., Mackie, K., Paratcha, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509494102 · Cited by 291 · cited 4×
“glucocorticoids or the inorganic ion Zinc [2,3,4,5,6,7].”
BackgroundInfluentialGreen, S. H., Rydel, R. E., Connolly, J. L., & Greene, L. A. (1986) · The Journal of cell biology · doi:10.1083/jcb.102.3.830 · Cited by 279 · cited 1×
“. The nnr5 PC12-TrkA, nnr5 PC12-TrkB and nnr5 PC12-TrkC cells (kindly provided by M. V. Chao) are NGF non-responding mutant PC12 cells stably transfected with TrkA, TrkB and TrkC cDNA, respectively”
BackgroundZinc-Mediated Transactivation of TrkB Potentiates the Hippocampal Mossy Fiber-CA3 Pyramid Synapse
Huang, Y. Z., Pan, E., Xiong, Z.-Q., & McNamara, J. O. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.026 · Cited by 274
Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect
Jeanneteau, F., Garabedian, M. J., & Chao, M. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709102105 · Cited by 215 · cited 4×
“glucocorticoids or the inorganic ion Zinc [2,3,4,5,6,7].”
BackgroundInfluentialLee, F. S., Rajagopal, R., Kim, A. H., Chang, P. C., & Chao, M. V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107421200 · Cited by 200 · cited 2×
“glucocorticoids or the inorganic ion Zinc [2,3,4,5,6,7].”
Marin, P., Nastiuk, K. L., Daniel, N., Girault, J.-A., Czernik, A. J., Glowinski, J., Nairn, A. C., & Prémont, J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-10-03445.1997 · Cited by 174 · cited 1×
“Cell lysates were prepared in boiling SDS (2%, w/v) as described previously”
MethodSelf-citationBath, K. G., Mandairon, N., Jing, D., Rajagopal, R., Kapoor, R., Chen, Z.-Y., Khan, T., Proenca, C. C., Kraemer, R., Cleland, T. A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4387-07.2008 · Cited by 165 · cited 1×
“-rhTrkB cells were incubated overnight with doxycycline. Cells were solubilized as for KIRA-ELISA assays and lysates were centrifuged at 14,000×g for 20 min at 4°C. Cleared supernatant was collected and proteins were subjected to SDS-PAGE. Detection of rhTrkB-ECFP and neuronal mouse TrkB were performed using anti-GFP…”
MethodForebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than “depressive”
Zörner, B., Wolfer, D. P., Brandis, D., Kretz, O., Zacher, C., Madani, R., Kadow, I. C. G., Lipp, H., Klein, R., Henn, F. A., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00418-9 · Cited by 165
Emerging themes in structural biology of neurotrophic factors
Ibáñez, C. F. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01266-1 · Cited by 163 · cited 1×
“Site-directed mutagenesis analyses, production of chimeric neurotrophins and mimetic peptides have highlighted specific and variable regions among neurotrophins that are important for the binding specificity and/or activation of their cognate Trk receptors [for reviews, see [17,18,19]].”
BackgroundThe protean actions of neurotrophins and their receptors on the life and death of neurons
Kalb, R. G. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.11.003 · Cited by 150 · cited 2×
“For instance, reports have demonstrated that necrosis of cultured cortical neurons can be induced by BDNF, a process abolished by inhibiting TrkB with antisense oligonucleotides or K252a [34] and absent in cultures made from cortices of TrkB-null mice [35].”
BackgroundNeurotrophic factors: From structure-function studies to designing effective therapeutics
Ibáñez, C. F. (1995) · Trends in biotechnology · doi:10.1016/s0167-7799(00)88949-0 · Cited by 150 · cited 1×
“Site-directed mutagenesis analyses, production of chimeric neurotrophins and mimetic peptides have highlighted specific and variable regions among neurotrophins that are important for the binding specificity and/or activation of their cognate Trk receptors [for reviews, see [17,18,19]].”
BackgroundIn vitro control of neuronal polarity by glycosaminoglycans
Lafont, F., Rouget, M., Triller, A., Prochiantz, A., & Rousselet, A. (1992) · Development · doi:10.1242/dev.114.1.17 · Cited by 143
Protecting Motor Neurons from Toxic Insult by Antagonism of Adenosine A2a and Trk Receptors
Mojsilovic-Petrovic, J., Jeong, G.-B., Crocker, A., Arneja, A., David, S., Russell, D., & Kalb, R. G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1856-06.2006 · Cited by 143 · cited 4×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
BackgroundInfluentialDesign of Potent Peptide Mimetics of Brain-derived Neurotrophic Factor
O'Leary, P. D., & Hughes, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303209200 · Cited by 129
Castrén, E., & Rantamäki, T. (2010) · CNS Drugs · doi:10.2165/11530010-000000000-00000 · Cited by 123
Neurotrophic factors and the pathophysiology of schizophrenic psychoses
Durany, N., & Thome, J. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.06.020 · Cited by 111 · cited 3×
“The conclusions drawn from these data are not always coherent, especially for those regarding psychiatric diseases, such as schizophrenic psychoses for instance [16].”
BackgroundSmall Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses
LeSauteur, L., Wei, L., Gibbs, B. F., & Saragovi, H. U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6564 · Cited by 111 · cited 1×
“active peptidomimetics of neurotrophins [see examples in [20,21,22,23,24,25,26,27]], demonstrating the feasibility of this strategy.”
BackgroundThe Tyrosine Kinase Fyn Determines the Localization of TrkB Receptors in Lipid Rafts
Pereira, D. B., & Chao, M. V. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4587-06.2007 · Cited by 109 · cited 1×
“This basal activation of TrkB may selectively occur in densely packed area throughout soma, dendrites and axons, at the plasma membrane but also in intracellular vesicles [32,33].”
BackgroundThe neurotrophic receptor TrkB: a drug target in anti-cancer therapy?
Desmet, C. J., & Peeper, D. S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5490-8 · Cited by 106 · cited 1×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
BackgroundA Designed Peptidomimetic Agonistic Ligand of TrkA Nerve Growth Factor Receptors
Maliartchouk, S., Feng, Y., Ivanisevic, L., Debeir, T., Cuello, A. C., Burgess, K., & Saragovi, H. U. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23211-9 · Cited by 105 · cited 1×
“active peptidomimetics of neurotrophins [see examples in [20,21,22,23,24,25,26,27]], demonstrating the feasibility of this strategy.”
BackgroundGomes, R. A., Hampton, C., El-Sabeawy, F., Sabo, S. L., & McAllister, A. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2364-06.2006 · Cited by 95 · cited 1×
“This basal activation of TrkB may selectively occur in densely packed area throughout soma, dendrites and axons, at the plasma membrane but also in intracellular vesicles [32,33].”
BackgroundDopamine D1 Receptor-induced Signaling through TrkB Receptors in Striatal Neurons
Iwakura, Y., Nawa, H., Sora, I., & Chao, M. V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801553200 · Cited by 90 · cited 4×
“glucocorticoids or the inorganic ion Zinc [2,3,4,5,6,7].”
BackgroundInfluentialXie, Y., Tisi, M. A., Yeo, T. T., & Longo, F. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005071200 · Cited by 84 · cited 1×
“active peptidomimetics of neurotrophins [see examples in [20,21,22,23,24,25,26,27]], demonstrating the feasibility of this strategy.”
BackgroundMolecular Basis of Neurotrophin−Receptor Interactions
Pattarawarapan, M., & Burgess, K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030221q · Cited by 83 · cited 1×
“Site-directed mutagenesis analyses, production of chimeric neurotrophins and mimetic peptides have highlighted specific and variable regions among neurotrophins that are important for the binding specificity and/or activation of their cognate Trk receptors [for reviews, see [17,18,19]].”
BackgroundPotier, B., Jouvenceau, A., Epelbaum, J., & Dutar, P. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.06.040 · Cited by 77 · cited 1×
“Hippocampal slices (400 µm) were prepared as previously described”
MethodSelf-citationBDNF heightens the sensitivity of motor neurons to excitotoxic insults through activation of TrkB
Hu, P., & Kalb, R. G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01599.x · Cited by 61 · cited 1×
“Therefore, in conditions in which hyperactivity of the BDNF/ TrkB system increases the vulnerability of neurons to excitotoxic insults [10,34,35,36], cyclotraxin-B can be used as a neuroprotective agent by maintaining the receptors in a minimal active state.”
BackgroundO'Leary, P. D., & Hughes, R. A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041712.x · Cited by 49
Fletcher, J. M., Morton, C. J., Zwar, R. A., Murray, S. S., O'Leary, P. D., & Hughes, R. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802789200 · Cited by 49 · cited 1×
“active peptidomimetics of neurotrophins [see examples in [20,21,22,23,24,25,26,27]], demonstrating the feasibility of this strategy.”
BackgroundRole of variable beta-hairpin loop in determining biological specificities in neurotrophin family.
Ilag, L. L., Lönnerberg, P., Persson, H., & Ibáñez, C. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32111-7 · Cited by 47
TrkA Receptor “Hot Spots” for Binding of NT-3 as a Heterologous Ligand
Ivanisevic, L., Zheng, W., Woo, S. B., Neet, K., & Saragovi, H. U. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701996200 · Cited by 43 · cited 1×
“active peptidomimetics of neurotrophins [see examples in [20,21,22,23,24,25,26,27]], demonstrating the feasibility of this strategy.”
BackgroundTargeting TrkB neurotrophin receptor to treat depression
Rantamäki, T., & Castrén, E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.705 · Cited by 40 · cited 1×
“BDNF and TrkB have been shown to regulate development of depression-like phenotypes and anxiety-related behaviors [14,40,41,42], depicting TrkB as a promising target for the development of new therapeutic compounds [13,43].”
BackgroundTrkB mediates BDNF-induced potentiation of neuronal necrosis in cortical culture
Kim, H. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00103-7 · Cited by 40 · cited 12×
“Cells were treated for 20 min with K252a prior to treatment with (closed circle) or without (closed square) BDNF (4 nM).”
BackgroundInfluentialSadick, M. D., Galloway, A., Shelton, D. L., Hale, V. G., Weck, S., Anicetti, V., & Wong, W. L. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3614 · Cited by 26 · cited 2×
“TrkB activity was quantified using the previously described KIRA-ELISA assay [28] with slight modifications.”
MethodA peptidomimetic of NT-3 acts as a TrkC antagonist
Brahimi, F., Malakhov, A., Lee, H. B., Pattarawarapan, M., Ivanisevic, L., Burgess, K., & Saragovi, H. U. (2009) · Peptides · doi:10.1016/j.peptides.2009.07.015 · Cited by 25
Molecular Basis of Neurotrophin—Receptor Interactions
Pattarawarapan, M., & Burgess, K. (2004) · ChemInform · doi:10.1002/chin.200411274 · Cited by 7
Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses.
LeSauteur, L., Wei, L., Gibbs, B. F., & Saragovi, H. U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.1249 · Cited by 6
Cited by
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
“Targeting the extracellular domains of the receptor TPKs and others by peptide-mimetics, ‘peptoids’ or antibodies is another special case of type-3 inhibitors (Fleishman et al., 2002; Udugamasooriya et al., 2008; Cazorla et al., 2010; Jura et al., 2011; Christopoulos et al., 2014).”
BackgroundOkamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Metadata
- Authors
- Cazorla, M., Jouvenceau, A., Rose, C., Guilloux, J.-P., Pilon, C., Dranovsky, A., & Prémont, J.
- Affiliations
- Inserm (FR)
- New York State Psychiatric Institute (US)
- Corresponding author
- Cazorla, Maxime
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-03-19
- Volume
- 5
- Issue
- 3
- Pages
- e9777
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2841647
- OpenAlex
- W1977999433
- Cited by
- 99
- References
- 62
- Citations by year
- 2026: 7 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 9 · 2021: 7 · 2020: 5 · 2019: 1 · 2018: 10 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 8
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- National Institute of Mental Health (R01MH091844, K08MH079088)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- TrkB receptor, brain-derived neurotrophic factor, anxiolytic effects, peptidomimetic inhibitors, allosteric inhibition, synaptic plasticity, neuronal differentiation, antidepressant-like effects, brain disorders, lead compounds
- MeSH terms
- Animals, Antidepressive Agents, Brain, Brain Diseases, Electrophysiology, Enzyme-Linked Immunosorbent Assay, Male, Neurons, Peptides, Cyclic, Phosphorylation, Anti-Anxiety Agents, PC12 Cells, Rats, Sprague-Dawley, Long-Term Potentiation, Brain-Derived Neurotrophic Factor, Receptor, trkB, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.